The role of a community pharmacist in diabetes education

Journal of Endocrinology, Metabolism and Diabetes of South Africa

Volumn 14, Issue 3, 2009, Pages 148-150

  Berg, Jeannie ^a   Dodd, S A ^a   Dodd, S ^a  

^a Kosmos Pharmacy   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

BLOOD GLUCOSE MONITORING; CHRONIC PATIENT; DIABETES CONTROL; DIABETES EDUCATION; DISEASE COURSE; EVIDENCE BASED PRACTICE; HEALTH PROGRAM; HUMAN; HUMAN RELATION; INSULIN TREATMENT; MEDICAL PRACTICE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHARMACIST; PHARMACIST ATTITUDE; PRESCRIPTION; QUALITY OF LIFE; REVIEW; SELF MONITORING;

EID: 78649670849     PISSN: 16089677     EISSN: None     Source Type: Journal    
DOI: 10.1080/22201009.2009.10872214     Document Type: Review

References (32)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [comment]. Lancet 1998;352:837-53 [erratum appears in Lancet 1999 Aug 14;354(9178):602].
3. Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ 2000;320:1373-8. (Pubitemid 30261117)
4. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999;22:1125-36.
5. Weingarten S, Henning J, Badamgarav E, et al. Interventions used in disease management programmes for patients with chronic illness - which ones work? Meta-analysis of published reports. BMJ 2002;325:1-8.
6. Diehl AK, Bauer RL, Sugarek N. Correlates of medication compliance in non-insulin dependent diabetes mellitus. South Med J. 1987;80:332-5.
7. Paes AHP, Bakker A, Soe-Agnie CJ. Impact of dosage frequency in patient compliance. Diabetes Care. 1997;20:1512-17.
8. Nagasawa M, Smith MC, Barnes Jr JH, Fincham JE. Meta-analysis of correlates of diabetes patients' compliance with prescribed medications. Diabetes Educ. 1990;16:192-200.
9. Haynes RB. Determinants of compliance: the disease and the mechanics of treatment. In: Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore: John Hopkins University Press; 1979, p. 49-62.
10. Blake SG, Hunter TS, Kost TM. Ensuring a role in diabetes disease management programs. J Pharm Pract 1999;12:155-62.
11. Jacobson J. Inspiring patients to meet their treatment goals. Am J Health-Syst Pharm 2000;57:1032-5. (Pubitemid 30619099)
12. Johnson LC, Beach E. The importance of the pharmacist's expanding role on the diabetes team: reinforcing nutritional guidelines for improved glycemic control. Pharm Pract Manage Q 1997;17(3):32-44.
13. Rosenqvist U. Patient education - new trends in Sweden. Patient Educ Couns 2001;44:55-8.
14. Sarkadi A, Rosenqvist U. Study circles at the pharmacy - a new model for diabetes education in groups. Patient Educ Couns 1999;37:89-96.
15. Van Veldhuizen-Scott MK, Widmer LB, Stacey SA, Popovich NG. Developing and implementing a pharmaceutical care model in an ambulatory care setting for patients with diabetes. Diabetes Educator 1995;21:117-23.
16. Teh R, Chen T, Krass I. Consumer perspectives of pharmacist delivered health promotion and screening services, Int J Pharm Pract 9 (2001)261-7. (Pubitemid 34038328)
17. McElnay J, Nicholl A, Grainger-Rousseau T. The role of community pharmacist - a survey of public opinion in N Ireland, Int J Pharm Pract 2(1993)95-100.
18. Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management [comment]. Ann Pharmacother 1996;30:238-43.
19. Davidson MB, Karlan VJ, Hair TL. Effect of a pharmacist- managed diabetes care program in a free medical clinic. Am J Med Qual 2000;15:137-42.
20. Irons BK, Lenz RJ, Anderson SL, Wharton BL, Habeger B, Anderson HGJ. A retrospective cohort analysis of the clinical effectiveness of a physician - pharmacist collaborative drug therapy management diabetes clinic. Pharmacotherapy 2002;22:1294-1300. (Pubitemid 35155082)
21. Clifford RM, Batty KT, Davis TME, Stein G, Stewart G. A randomized controlled trial of a pharmaceutical care programme for high-risk diabetic patients in an outpatient clinic. Int J Pharm Pract 2002;10:85-9.
22. Rothman RL, Malone R, Bryant B, et al. A randomized trial of primary care-based disease management program to improve cardiovascular risk factors and glycated haemoglobin levels in patients with diabetes. Am J Med 2005;118:276-84.
23. Berringer R, Shibley MC, Cary CC, Pugh CB, Powers PA, Rafi JA. Outcomes of a community pharmacy-based diabetes monitoring program [comment]. J Am Pharm Assoc 1999;39:791-7.
24. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003;43:73-84.
25. Armour CL, Taylor SJ, Hourihan F, Smith C, Krass I. Implementation and evaluation of Australian pharmacists' diabetes care services. J Am Pharm Assoc 2004;44:455-66.
26. Clifford RM, Batty KT, Davis W, Davis TME. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes. Diabetes Care 2005;28: 771-6.
27. Krass I, Armour C, Mitchell B, et al. The pharmacy diabetes care program: evaluating the impact of a diabetes service model delivered by community pharmacists in Australia. Diabet Med 2007;24:677-83. (Pubitemid 46808869)
28. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med 1993;329:977-86.
29. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study, Diabetes Res Clin Pract 1995;28:103-17.
30. Welschen LMC, Bloemendal E, Nijpels G, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review, Diabetes Care 2005;28(6):1510-7.
31. Janssen M, Manuel P, Wallace J, Weiping Z, Parks JL. Ascensia® WinGLUCOFACTS® Professional Software Improves Diabetes Health Outcomes, Journal of Diabetes Science and Technology 2007:1:47-53
32. Pearson J, Bergenstal R. Fine-tuning control: pattern management versus supplementation. View 1. Pattern management: an essential component of effective insulin management, Diabetes Spectrum 2001;14(2):75-8.